<DOC>
	<DOCNO>NCT00485576</DOCNO>
	<brief_summary>This study design test role complement late asthmatic response allergen challenge mild asthma , indicator possible role complement broad asthmatic population .</brief_summary>
	<brief_title>Safety Efficacy Study Eculizumab Patients With Mild Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>diagnose stable , mild , allergic asthma ; history episodic wheeze shortness breath ; sexually active woman childbearing potential must use contraceptive entire duration study ; willing able give inform consent ; positive methacholine challenge ; positive skin prick test common aeroallergens ; positive allergeninduced early late phase bronchoconstrictor response FEV1 least 70 % predict value ; PC20 baseline within 1 double dose measure screening Exclusion : active bacterial infection ; respiratory tract infection worsen asthma within 28 day use inhaled topical steroid within 28 day use systemic corticosteroid within 90 day ; use cromoglycate , nedocromil , leukotriene receptor antagonists inhibitor 5lipoxygenase within 14 day ; use antihistamine , immunosuppressive , medication interact eculizumab ; use theophyllinecontaining agent ( type ) , longacting beta 2agonists ( salmeterol , formoterol ) longacting anticholinergic within 14 day ; use NSAIDs prior spirometry ; use tobacco product currently within previous 12 month ; smoke history &gt; 10 packyears ; lung disease mild allergic asthma ; patient LAR vaccinate Neisseria meningitidis ; hepatitis B HIV infection ; parasitic infection ; participation investigational drug trial ; pregnant breast feed woman , intend conceive course trial ; know hypersensitivity treatment drug excipients ; history illicit drug use alcohol abuse within previous year ; clinically significant abnormality screen lab test result ; abnormal chest Xray ; chronic use medication treatment allergic lung disease shortacting beta2agonists ipratropium bromide ; medical condition might interfere subject 's participation study confound assessment subject ; unwilling inability comply study protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>